Skip to search formSkip to main contentSkip to account menu

efegatran

Known as: D-methyl-phenylalanyl-prolyl-arginal, Me-Phe-Pro-Arg-H 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (3)

AnticoagulantsOligopeptidesPlatelet Aggregation Inhibitors

Narrower (2)

GYKI 14766LY 294468
efegatran sulfate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Direct thrombin inhibitors in acute coronary syndrome patients undergoing percutaneous coronary intervention: special effects in selected patients?
This editorial refers to ‘Direct thrombin inhibitors in acute coronary syndromes: effects in patients undergoing early… 
Review
2003
Review
2003
Influence of Different Anticoagulant Agents on Fibrinopeptide A Generation
The purpose of this study was to determine the in vitro effects of different anticoagulant drugs on fibrinopeptide A (FPA… 
2002
2002
Effect of some new thioglycosides on endotoxin-induced disseminated intravascular coagulation in rabbits.
2002
2002
Direct thrombin inhibitors in acute coronary syndromes
Review
2001
Review
2001
Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs
Abstract. Small-molecule direct thrombin inhibitors represent a new class of anticoagulants and are emerging as antithrombotic… 
Review
1999
Review
1999
Thrombogenesis in myocardial infarction and related syndromes: the role of molecular markers in diagnosis and management.
Anticoagulant therapy has undergone some major developments in recent years. Conventional drugs that produce anticoagulant… 
1998
1998
The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin.
The thrombin inhibitors argatroban, efegatran, NAPAP, CH 1091, CH 248, inogatran and melagatran have been characterised with… 
1996
1996
A Family of Arginal Thrombin Inhibitors Related to Efegatran
Three new tripeptide arginal thrombin inhibitors were shown to have potent anticoagulant and antithrombotic activity: D-MePhg-Pro… 
1996
1996
Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of…
BACKGROUND There is a paucity of data regarding the antithrombotic pharmacology of the drug-drug interactions between the newer… 
1996
1996
Preclinical and Clinical Pharmacology of Efegatran (LY294468) : A Novel Antithrombin for the Treatment of Acute Coronary Syndromes
Efegatran (LY294468), a tripeptide arginal in hibitor of the catalytic site of thrombin, is being devel oped as a parenteral… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)